In vitro and in vivo correlation of the effect of granulocyte-macrophage colony-stimulating factor gene transfer on the tumorigenicity and immunogenicity of B16 melanoma

International Journal of Oncology

Volumn 9, Issue 6, 1996, Pages 1267-1276

  Wang, Jie ^a   Wei, Sung Jan ^b   Yang, Wen K ^b   Lin, Wen Chang ^b   Yang, Den Mei ^b   Whang Peng, Jacqueline ^b   Ting, Chou Chik ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

gene transfer; GM CSF; tumor immunity

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; FEMALE; GENE TRANSFER; IMMUNOGENICITY; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029833161     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.9.6.1267     Document Type: Article

References (39)

1. Tepper RI, Pattengale PK and Leder P: Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57: 503-512, 1989.
2. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons J, Karasuyama H, Vogelstein B and Frost P: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell 60: 397-403, 1990.
3. Gansbacher B, Zier K, Daniels B, Cronin K, Banerji R and Gilboa E: Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217-1224, 1990.
4. Golumbek PT, Lazenby A, Levitsky HI, Jaffe LM, Karasuyma H, Baker M, Pardoll DM: Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254: 713-716, 1991.
5. Li W, Diamantstein T and Blankenstein T: Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4. Mol Immunol 27: 1331-1337, 1990.
6. Porgador A, Tzehoval E, Katz A, Vadai E, Revel M, Feldman M, Eisenbach L: Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 52: 3679-3686, 1992.
7. + cell-dependent tumor rejection. J Exp Med 174: 1291-1298, 1991.
8. Aoki T, Tashiro K, Miyatake S-I, Kinashi T, Nakano T, Oda Y, Kikuchi H and Honjo T: Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA 89: 3850-3854, 1992.
9. Nastala C, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ and Lotze MT: Recombinant IL-12 administration induced tumor regression in association with INF-γ production. J Immunol 153: 1697-1706, 1994.
10. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF and Gately MK: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223-1230, 1993.
11. Colombo MP, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M, Mavillo F and Parmiani G: Granulocyte colony-stimulating factor gene transfer suppress tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 173: 889-897, 1991.
12. Dranoff G, Jaffe E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D and Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543, 1993.
13. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K and Gilboa E: Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50: 7820-7825, 1990.
14. Watanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama E-I, Taniyama T and Sakata T-A: Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 86: 9456-9460, 1989.
15. Blankenstein T, Qin Z, Uberla K, Muller W, Rosen H, Volk H-D and Diamantstein T: Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer. J Exp Med 173: 1047-1052, 1991.
16. Teng MN, Park BH, Koeppen HKW, Tracey KJ, Fendly BM and Schreiber H: Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci USA 88: 3535-3539, 1991.
17. Laning J, Kawasaki H, Tanaka E, Luo Y and Dorf ME: Inhibition of in vivo tumor growth by the β chemokine, TCA3. J Immunol 153: 4625-4635, 1994.
18. Rollins BJ and Sunday ME: Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol Cell Biol 11: 3125-3131, 1991.
19. Colombo MP and Forni G: Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15: 48-51, 1994.
20. Leo O, Foo M, Sachs DH, Samelson LE and Bluestone JA: Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 84: 1374-1378, 1987.
21. Marshak-Rothstein A, Fink P, Gridley T, Raulet DH, Bevan MJ and Gefter ML: Properties and application of monoclonal antibodies directed against determinants of Thy-1 locus. J Immunol 122: 2491-2497, 1979.
22. Dialynas DP, Wilde DB, Marrack P, Pierres A, Wall KA, Hassen W, Otten G, Loken MR, Pierres M, Kappler J and Fitch F: Characterization of the murine antigenic determinants designated L3T4a, recognized by monoclonal antibody GK 1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class I MHC antigenic reactivity. J Immunol Rev 74: 29-56, 1983.
23. Fidler IJ: Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 35: 218-234, 1975.
24. Boone LR, Myer FE, Yang DM, Kiggans JO, Koh CK, Tennant RW, Yang WK: Analysis of recombinant DNA clones of the endogenous BALB/c murine leukemia virus WN1802N: Variation in long terminal repeat length. J Virol 45: 484-488, 1983.
25. Gough NM, Gough J, Metcalf D, Kelso A, Grail D, Nicola NA, Burgess AW and Dunn AR: Molecular cloning of cDNA encoding a murine haematopoietic growth regulator, granulocyte-macrophage colony stimulating factor. Nature 309: 763-767, 1984.
26. Miller AD, Baltimore C: Redesign of retrovirus packing cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 6: 2895-2902, 1986.
27. Cikes M, Friberg S and Klein G: Progressive loss of H-2 antigens with concomitant increase of cell surface antigen(s) determined by Moloney leukemia virus in cultured murine lymphoma. J Natl Cancer Inst 50: 347-362, 1973.
28. Dunn TB and Potter M: A transplantable mast cell neoplasm in the mouse. J Natl Cancer Inst 18: 587-595, 1957.
29. Gorer PA: Studies in antibody response of mice to tumor inoculation. Br J Cancer 4: 372-379, 1950.
30. Attia MA, DeOme KB and Weiss D: Immunology of spontaneous mammary carcinoma in mice. II. Resistance to rapidly and slowly developing tumor. Cancer Res 25: 451-457, 1965.
31. Yun YS, Hargrove ME and Ting CC: Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody. J Immunol 141: 1390-1397, 1988.
32. 125IUdR release assay for use with suspension target cells. J Immunol 115: 1351-1356, 1975.
33. Levitsky HI, Lazenby A, Hayashi RJ, and Pardoll DM: In vivo priming of two distinct anti-tumor effector populations: The role of MHC Class I expression. J Exp Med 179: 1215-1224, 1994.
34. Ting CC, Wang J, Hargrove ME: Reversal of multiple-site tumor cell-induced immunosuppression by specific cytokines and pharmacological agents. Immuno-pharmacology 30: 119-130, 1995.
35. Stoppacciaro A, Melani C, Parenza M, Mastracchio A, Bassi C, Baroni C, Parmiani G and Colombo M: Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon γ. J Exp Med 178: 151-161, 1993.
36. Ting CC and Hargrove ME: IL-4 regulation of a protein kinase C independent pathway for the generation of αCD3-induced activated killer cells. Cellular Immunol 140: 130-144, 1992.
37. Martinez GM, Gibbons RS, Garovoy MR and Aronson FR: IL-4 inhibits IL-2 receptor expression and IL-2-dependent proliferation of human T cells. J Immunol 144: 2211-2215, 1990.
38. Llorwnte L, Crevon Karray S, Defrance T, Banchereau J and Galanaue P: IL-4 counteracts the effect of IL-2 on antigen-activated B cells. Eur J Immunol 19: 765-769, 1989.
39. Powrie F, Menon S and Coffman RL: Interleukin-4 and interleukin-10 syngeries to inhibit cell-mediated immunity in vivo. Eur J Immunol 23: 3043-3049, 1993.